The FDA has cleared Complement Therapeutics GmbH’s (CTx) investigational new drug (IND) application for CTx001, its lead gene therapy candidate under clinical development to treat geographic atrophy secondary to age-related macular degeneration (AMD).

CTx001 - Complement Therap

Oct 23, 2025